Experimental Herpes Simplex Virus Type 1 Encephalitis: Treatment with 5-Trifluoromethyl-2′-Deoxyuridine
AUTOR(ES)
Clough, D. W.
RESUMO
5-Trifluoromethyl-2′-deoxyuridine (F3dThd) was evaluated for its neurotoxicity and for its ability to increase the life span of mice injected intracerebrally with herpes simplex virus type 1 (HSV-1) and F3dThd simultaneously. F3dThd showed no neurotoxicity at the highest concentration tested (100 mg/kg). Mice injected intracerebrally with HSV-1 died within 5 days postinfection. However, all mice injected concurrently with HSV-1 and 100 mg of F3dThd per kg lived through the termination of the experiment (60 days). Protection of mice from HSV-1 encephalitis by F3dThd has been shown to be dose dependent, with 100, 75, 50, and 25 mg of F3dThd per kg yielding a survival rate of 100, 90, 50, and 10%, respectively. HSV-1 titers in mouse brains receiving HSV-1 and 100 mg of F3dThd per kg concurrently were 100- to 1,000-fold lower at 2 to 4 days postinfection than control mice receiving HSV-1 alone. F3dThd was shown not to stimulate interferon production. Encephalitis caused by a ribonucleic acid virus, encephalomyocarditis virus, was not modified by F3dThd treatment.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=351972Documentos Relacionados
- HEp-2 Cell- and Herpes Simplex Virus Type 1- Induced Deoxythymidine Kinases: Inhibition by Derivatives of 5-Trifluoromethyl-2′-Deoxyuridine
- Treatment of experimental herpes simplex virus encephalitis with (E)-5-(2-bromovinyl)-2'-deoxyuridine in mice.
- Biological Effects of 5-Carboxy-2′-Deoxyuridine: Hydrolysis Product of 5-Trifluoromethyl-2′-Deoxyuridine
- Effect of Treatment with 5-Ethyl-2′-Deoxyuridine on Herpes Simplex Virus Encephalitis in Normal and Immunosuppressed Mice
- Effect of Treatment with 5-Ethyl-2′-Deoxyuridine on Herpes Simplex Virus Encephalitis in Normal and Immunosuppressed Mice
